On 23 January 2020, the US Food and Drug Administration (FDA) granted accelerated approval to tazemetostat (TAZVERIK, Epizyme, Inc.) for adults and paediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
Efficacy was investigated in a single-arm cohort (Cohort 5) of a multicentre trial (Study EZH-202, NCT02601950) in patients with histologically confirmed, metastatic or locally advanced epithelioid sarcoma. Patients were required to have INI1 loss, detected using local tests, and an Eastern Cooperative Oncology Group performance status of 0-2. Patients received tazemetostat 800 mg orally twice daily until disease progression or unacceptable toxicity. The major efficacy outcome measures were confirmed overall response rate (ORR) according to RECIST v1.1 (assessed by blinded independent central review) and duration of response.
The ORR for the 62 patients in Cohort 5 was 15% (95% confidence interval: 7%, 26%), with 1.6% having complete responses and 13% partial responses; 67% of those responding had responses lasting 6 months or longer.
The most common adverse reactions (incidence ≥20%) were pain, fatigue. nausea, decreased appetite, vomiting and constipation.
The recommended tazemetostat dose is 800 mg taken orally twice daily with or without food.
Full prescribing information for TAZVERIK is available here.
This indication is approved under accelerated approval based on ORR and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory tria
FDA granted tazemetostat orphan drug designation.
Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System.
For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact FDA’s Oncology Center of Excellence Project Facilitate.